Page 33 - Sun Pharma

Sun Pharma recalls over 17,500 bottles of nasal spray solution from US

The bottles are being recalled following a failure to meet the % RSD requirement in the test for Droplet Size during the 6 month long term stability test station

Sun Pharma eclipsed by 75% fall in Q3 net profit on weak US business

The results were below Bloomberg's revenue and profit estimate by over 5 per cent and 61 per cent, respectively

Sun Pharma Q3 net profit plunges 75% to Rs 3.6 bn on weak US sales

Total revenue from operations fell 16 percent to Rs 66.53 billion

Pharma shares gain; Sun Pharma hits seven-month high

Wockhadrt, Biocon, Ipca Laboratories, Glenmark Pharmaceuticals, Lupin and Cadila Healthcare were up more than 2% on the National Stock Exchange.

Sun Pharma's specialty business gets USFDA boost

Stock gained over 6% as FDA accepts application for new ophthalmic drug

Specialty drug boost for Sun Pharma

Valuations, however, already factor in some of the positives

Sun Pharma shares rise over 6% after USFDA accepts new drug application

The stock closed at 6.12 per cent to Rs 573.50 on BSE

USFDA accepts Sun Pharma's new eye drug application

Shares of Sun Pharma were up 5.75 per cent at Rs 571.55 on the BSE

Sun Pharma up 4% on USFDA acceptance of new drug application

The stock was up 4% at Rs 564 on the BSE with trading volumes on the counter more than doubled.

Sun Pharma recalls two batches of diabetic drug from US market

Riomet is an oral diabetes medicine that helps control blood sugar level

Sun Pharma's specialty drugs face competition in US

The Mumbai-based pharma major reported 59% decline in its net profit for the quarter ending September to Rs 912 cr

No major respite for Sun Pharma

The Sun Pharmaceutical stock, after seeing some gains post September quarter results, is now marginally below pre-result levels despite the recent positive news flow. So, what's keeping sentiment low in the counter?First the positive part. The latest development pertains to the restart of supplies of some products to the US by Sun from its key plant in Halol (Gujarat). A Credit Suisse report, referring to IMS data, also indicates that Sun's oncology generics of Gleevac has gained market share sequentially in the December quarter (Q3) so far, on a trailing basis. The Gleevac generics, which has seen competitive pressures post Sun's exclusivity ended in FY17 and contributed $230 million to Sun's FY17 sales, was estimated to see its contribution drop by a third in FY18. So, the news of it gaining market share (19 per cent sequential revenue growth) is positive. This, coupled with Sun's re-entry into key segments such as neurology (Duloxetine, Carbidopa and Levodopa) and ENT (Azelastine ..

Sun Pharma recalls diabetes drug in US over microbial contamination

Use of contaminated Riomet potentially could result in a risk of infection, especially in the immunocompromised patient.

Sun Pharma shares dip 4%, m-cap drops by Rs 5,065 cr as Q2 net declines 59%

The scrip was the worst hit among the 30 Sensex blue chips

Sun Pharma profit slips 59%

Sun Pharma reported a decline in consolidated net profit in the second quarter of FY 2018

Sun Pharma Q2 net plunges 59% at Rs 912 cr

Analysts on average had expected a profit of Rs 827 crore, according to Thomson Reuters data

Sun Pharma: Taro provides some respite

Key triggers are in improvement in ex-Taro performance, resolution of US FDA issues

Sun Pharma, Dr Reddy's, Glenmark gain even after price-fixing charges in US

Nifty Pharma index, the largest gainer among sectoral indices, was up 2.8%, as compared to unchanged in Nifty 50 index at 10,441 at 09:46 AM

Pharma shares in focus; Sun Pharma gains 4% in intra-day deals

Sun Pharma, Unichem Lab, Ipca Lab, Wockhardt, Marksans Pharma, Cadila Healthcare and Aurobindo Pharma were up in the range of 3% to 8%

Sun Pharma gets USFDA nod for generic drug to treat cardiac problems

As per IMS, Coreg CR had annual sales of around $208 million in the US for the 12 months ended August 2017